NCT00440518

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 218 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.

Detailed description

This study is for subjects who have been diagnosed with migraine for at least one year and who are currently taking an effective abortive medication(s).

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Lacosamide	Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
OTHER	Placebo	Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
DRUG	Lacosamide	Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.

Timeline

• Start date: 2007-02-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2007-02-27
• Last updated: 2018-07-17
• Results posted: 2009-09-11

Locations

24 sites across 1 country: United States